Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invivyd ( (IVVD) ) has shared an update.
On October 6, 2025, Invivyd, Inc. announced that the U.S. FDA has cleared its Investigational New Drug application for VYD2311, a vaccine-alternative antibody aimed at preventing COVID-19. The company plans to begin two pivotal clinical trials, DECLARATION and LIBERTY, by the end of 2025, with results expected by mid-2026. These trials aim to provide data on the safety and efficacy of VYD2311, potentially offering a new option for COVID-19 prevention that could influence medical practices and provide at-risk populations with more choices for protection.
The most recent analyst rating on (IVVD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary technology platform to develop innovative antibodies, including monoclonal antibodies for COVID-19 prevention.
Average Trading Volume: 5,476,302
Technical Sentiment Signal: Buy
Current Market Cap: $226.1M
Learn more about IVVD stock on TipRanks’ Stock Analysis page.